Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Reddy Laboratories" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Reddy Laboratories for you to read. Along with our medical data and news we also list Reddy Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of Reddy Laboratories Companies for you to search.
NewsDr. Reddy’s Laboratories has launched an over-the-counter therapeutic equivalent generic version of Xyzal Allergy 24HR Tablets in the United States market.
Dr. Reddy’s Laboratories has signed a distribution agreement with UCB to supply the latter’s epilepsy drug Briviact in India. As...Read More... The post Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech appeared first on Pharmaceutical Technology.
NewsDr. Reddy's Laboratories announces final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. market.
Dr. Reddy’s Laboratories Ltd.INVESTOR RELATIONSSAUNAK SAVLA, +firstname.lastname@example.orgMEDIA RELATIONSCALVIN PRINTER, +email@example.com Read more...
The US FDA has issued a Form 483 with four observations to an API facility in Hyderabad, India run by Dr Reddyâs Laboratories.
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District … Continue reading → Cet article Dr. Reddy’s Laboratories defends its right to lau...
India’s Dr Reddy’s Laboratories has announced the filing of New Drug Application (NDA) for its migraine…
Dr. Reddyâs Laboratories has announced receipt of a US FDA establishment inspection report regarding two active pharmaceutical ingredient plants in Hyderabad, India.
On 18 December 2017, the District of New Jersey filed a complaint against Dr. Reddy’s Laboratories for failing to comply with the Poison Prevention Packaging Act (PPPA) and the Consumer Product Safety Act (CPSA). Just over a month later, the district court handed down a $5 million penalty and entered a permanent injunction to prevent Dr. Reddy’s from distributing prescription drugs not in chi...
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent …
UCB has granted Dr. Reddy's Laboratories exclusive rights to market Briviact, or brivaracetam, in India. -More-
The US FDA has announced that over 236,000 bottles of statins will be voluntarily recalled by Dr. Reddyâs Laboratories, after issues were found with impurities.
NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter therapeutic equivalent generic ver...
Indian pharmaceutical company Dr Reddy’s Laboratories has announced that the US District Court in New Jersey has issued a temporary restraining...Read More... The post US court issues a restraint order against Dr Reddy’s new drug appeared first on Pharmaceutical Technology.
Dr Reddy's Laboratories (DRL), a Rs. 14,200 crore plus pharma major, has suffered another setback during the fourth quarter ended March 2018 on account of stagnant sales, significant higher tax provisions, price erosion
Indivior has requested a temporary restraining order against Dr. Reddyâs Laboratories to prevent further sales of its generic buprenorphine and naloxone sublingual film product in the US.
Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership tra...
Migraine sufferers could have a new treatment option. India-based Dr. Reddy’s Laboratories and its subsidiary Promius Pharma, LLC filed a NDA with the U.S. FDA for approval of migraine candidate DFN-02.
Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and...
Stock Monitor: Amphastar Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Dr. Reddy's Laboratories Ltd (NYS...
Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction.
Dr Reddy’s Laboratories is betting on complex product launches to power an improvement in its bottom line after reporting a...
Dr Reddy’s Laboratories problem with ensuring products reach the market at a quality the FDA deems acceptable is no secret and, unfortunately for the company, it has once again been slapped with a recall of over 80,000 bottles of Atorvastatin. Only last month, it was forced to recall more than 1,000 Docetaxel injection vials used to treat breast cancer and was also hit by a fine for improperly p...
A US court has approved Indivior’s preliminary injunction (PI) preventing Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.
A US court has approved Indivior’s preliminary injunction (IP) preventing India-based Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.